Unknown Cancer NIHR-supported project Digestion, Kidneys & Other Organs
QRL-201-01 - Multi-center, randomized, double-blind, placebo-controlled multiple-ascending dose study to evaluate the safety and tolerability of QRL-201 in amyotrophic lateral sclerosis
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Andrea Malaspina (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
A multi-center, randomized, double-blind, placebo-controlled multiple ascending dose study to evaluate the safety and tolerability of QRL-201 in Amyotrophic Lateral Sclerosis. (Phase 1).
A multi-center, randomized, double-blind, placebo-controlled multiple-ascending dose study to evaluate the safety and tolerability of qrl-201 in amyotrophic lateral sclerosis
A study evaluating the safety and tolerability of QRL-201 in ALS
A35-004 Phoenix - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
Master protocol title: A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS) Sub-protocol title: Randomized double-blind placebo-controlled phase 3 trial of Lithium Carbonate in Amyotrophic Lateral Sclerosis
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know